학술논문

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-2 and/or BCL-6 Gene Rearrangements or Increase Copy Number
Document Type
Abstract
Source
In Blood 5 November 2020 136 Supplement 1:38-39
Subject
Language
ISSN
0006-4971